Idenix Pharmaceuticals, Inc. Announces Appointment of Douglas Mayers, M.D. as Executive Vice President and Chief Medical Officer
January 08 2007 - 4:00PM
PR Newswire (US)
CAMBRIDGE, Mass., Jan. 8 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ:IDIX) today announced the appointment
of Douglas Mayers, M.D. to the position of executive vice president
and chief medical officer. Reporting to Jean-Pierre Sommadossi,
Ph.D., chairman and chief executive officer of Idenix, Dr. Mayers
will be responsible for the company's clinical development
activities. Dr. Mayers will replace Nathaniel Brown, M.D., who is
resigning as an executive officer, but remaining affiliated with
Idenix as a Senior Medical Advisor. The transition of the role of
chief medical officer will occur at the end of January. "Dr.
Mayers' nearly 20 years of medical and clinical development
experience in infectious diseases will be important as we seek to
advance our hepatitis C and HIV clinical programs and to expand our
pipeline with additional clinical drug candidates," said Dr.
Sommadossi. "We are delighted to have Dr. Mayers join the senior
management team of Idenix." Dr. Sommadossi added, "I want to thank
Dr. Brown for his valuable contributions to Idenix. Under his
leadership, we successfully developed telbivudine for the treatment
of hepatitis B from phase I through FDA approval in just six years
and significantly advanced our hepatitis C clinical program. We
look forward to continuing our working relationship with Dr.
Brown." Prior to joining Idenix, Dr. Mayers was International
Head/Vice President, Therapeutic Area of Virology with Boehringer
Ingelheim for five years and was responsible for the strategic
coordination of all HIV and hepatitis clinical trials in phases I
through IV. Prior to joining industry, Dr. Mayers conducted
clinical trials in HIV research during his seventeen years in the
Navy and his subsequent three years as the Head of Infectious
Diseases with Henry Ford Hospital. Board certified in internal
medicine and infectious diseases, Dr. Mayers completed his M.D. at
the University of Pennsylvania. Dr. Mayers remains in the Navy
Reserves and currently holds the rank of Captain. About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is a biopharmaceutical company engaged in the
discovery, development and commercialization of drugs for the
treatment of human viral and other infectious diseases. Idenix's
current focus is on the treatment of infections caused by hepatitis
B virus, hepatitis C virus and HIV. For further information about
Idenix, please refer to http://www.idenix.com/. Forward-looking
Statements This press release contains "forward-looking statements"
within the meaning of The Private Securities Litigation Reform Act
of 1995. Such forward- looking statements can be identified by the
use of forward-looking terminology such as "advance," "expand" or
similar expressions and implied statements with respect to Idenix
clinical development programs in HIV, hepatitis B or C, or any
potential pipeline candidates, Dr. Mayers' anticipated
contributions to Idenix and Dr. Brown's continuing working
relationship. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results,
performance or achievements expressed or implied by such
statements. There can be no guarantees that Idenix will
successfully advance any clinic product candidate or other
component of our potential pipeline. In particular, management's
expectations could be affected by the unexpected regulatory actions
or delays; uncertainties relating to results of clinical trials,
including additional data relating to the ongoing clinical trials
evaluating its product candidates; the company's ability to obtain
additional funding required to conduct its research, development
and commercialization activities; the company's dependence on its
collaboration with Novartis Pharma AG; the ability of the company
to attract and retain qualified personnel; competition in general;
and the company's ability to obtain, maintain and enforce patent
and other intellectual property protection for its other product
candidates and its discoveries. These and other risks which may
impact management's expectations are described in greater detail
under the caption "Risk Factors" in the company's quarterly report
on Form 10-Q for the quarter ended September 30, 2006 and filed
with the Securities and Exchange Commission and other filings that
the company makes with the Securities and Exchange Commission. All
forward-looking statements reflect the company's expectations only
as of the date of this release and should not be relied upon as
reflecting the company's views, expectations or beliefs at any date
subsequent to the date of this release. Idenix anticipates that
subsequent events and developments may cause these views,
expectations and beliefs to change. However, while Idenix may elect
to update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. Idenix
Pharmaceuticals' Contacts: Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838 DATASOURCE: Idenix
Pharmaceuticals, Inc. CONTACT: Media, Teri Dahlman,
+1-617-995-9905, or Investors, Amy Sullivan, +1-617-995-9838, both
of Idenix Pharmaceuticals, Inc. Web site: http://www.idenix.com/
Copyright
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More Idenix Pharmaceuticals (MM) News Articles